These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 25046567)

  • 1. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
    Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
    J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
    Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.
    Schmiedel BJ; Werner A; Steinbacher J; Nuebling T; Buechele C; Grosse-Hovest L; Salih HR
    Mol Ther; 2013 Apr; 21(4):877-86. PubMed ID: 23380816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
    Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
    Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
    Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
    Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
    Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [NKG2D-mediated natural killer cell cytotoxicity against myeloid leukemia cells OUN-1].
    Lu XZ; Cai XH; Ma LD; Chen BA
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):444-7. PubMed ID: 22967377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
    Ding H; Yang X; Wei Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.